Bedrijfsoverzicht
Accuray Incorporated is a specialized manufacturer engaged in the design, development, manufacture, and sale of advanced radiosurgery and radiation therapy systems intended for the treatment of tumors across a global footprint including the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. Operating within the healthcare sector specifically under the medical devices industry, the company focuses on providing critical oncology infrastructure that supports precision cancer care protocols worldwide. The entity employs a workforce of 990 individuals to support its operations and maintain its technological capabilities in radiation oncology. In terms of market valuation, Accuray Incorporated holds a market capitalization of $46.31M and generates trailing twelve-month revenue of $436.97M. These figures indicate that while the company possesses significant operational scale and revenue generation capabilities, its market cap reflects a small-cap classification relative to its revenue base, suggesting a valuation compressed relative to its annual sales performance.
Financiële gezondheid
Accuray Incorporated reported revenue of $436.97M for the trailing twelve months, yet recorded a net income of -$35,622,000 and an EBITDA of -$1,700,000. The substantial gap between the reported revenue of $436.97M and the net loss of -$35,622,000 reveals a cost structure where operating expenses, including cost of goods sold and administrative overhead, significantly exceed gross profits before interest and taxes. The company generated free cash flow of -$803,500, which indicates that current cash outflows for operations and capital expenditures are outpacing cash inflows from sales, thereby limiting immediate financial flexibility for discretionary spending. Profitability is further constrained by a gross margin of 27.8%, an operating margin of -5.4%, and a profit margin of -8.2%. The negative operating and profit margins demonstrate that the company is currently unable to convert its sales into net earnings or operating cash, signaling ongoing operational challenges in covering fixed and variable costs. On the balance sheet, the company holds $41.30M in cash while carrying $174.23M in debt, resulting in a debt-to-equity ratio of 326.14. This high leverage level indicates a highly leveraged balance sheet where debt obligations substantially outweigh equity capital, increasing financial risk under elevated interest rates. Liquidity is assessed via a current ratio of 1.47, which suggests the company maintains sufficient current assets to cover its short-term liabilities, though the margin is relatively tight given the negative EBITDA. Return on equity stands at -70.3% and return on assets is -1.2%, metrics that reveal management is currently destroying value rather than generating returns on the capital invested by shareholders or creditors.
Waarderingsbeoordeling
The trailing P/E ratio is listed as N/A due to the lack of positive earnings, while the forward P/E is recorded at -13.00, implying that the market is pricing in future earnings recovery or that current expectations are based on negative earnings projections. The absence of a positive trailing P/E ratio highlights the current inability to value the stock based on historical earnings power, shifting focus to asset-based or sales-based metrics. The price-to-book ratio is 0.87, indicating that the stock is trading below its book value per share, which often suggests the market is discounting the company's intangible assets or anticipating future operational hurdles. Alternative valuation metrics such as a price-to-sales ratio of 0.11 and an EV/EBITDA of -105.44 further illustrate the market's cautious stance, as the negative EV/EBITDA reflects the company's current unprofitability. The stock has a 52-week high of $2.10 and a 52-week low of $0.33, meaning the current price sits within a wide trading range that captures significant volatility. The beta value of 1.32 indicates that the stock is more volatile than the broader market, moving with greater intensity than the S&P 500 during periods of market stress or rally.
Growth & Income
Revenue growth year-over-year stands at -12.0%, while earnings growth is N/A due to the current net loss position. The negative revenue growth indicates a contraction in sales compared to the prior year, and the lack of earnings growth is consistent with the company's financial performance of generating a net loss rather than profit. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, meaning the company reinvests all available cash flow into growth initiatives or debt repayment rather than distributing income to shareholders. The overall growth and income profile for Accuray Incorporated is characterized by declining revenue, negative earnings, and a complete absence of dividend distributions, reflecting a period of financial restructuring or market headwinds within the medical devices sector.